HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
2.
GraniG, LamartinaL, DuranteC, FilettiS, CooperDS. 2017. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol, 6:500–514.
3.
DionigiG, KraimpsJL, SchmidKW, HermannM, Sheu-GrabellusSY, De WaillyP, BeaulieuA, TandaML, SessaF. 2014. Minimally invasive follicular thyroid cancer (MIFTC)—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg, 399:165–184.
4.
DaviesL, WelchHG. 2006. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 295:2164–2167.
5.
AsaSL. 2017. The evolution of differentiated thyroid cancer. Pathology, 49:229–237.
6.
CiprianiNA, NagarS, KaplanSP, WhiteMG, AnticT, SadowPM, Aschebrook-KilfoyB, AngelosP, KaplanEL, GroganRH. 2015. Follicular thyroid carcinoma: how have histologic diagnoses changed in the last half-century and what are the prognostic implications? Thyroid. 25:1209–1216.
7.
HirokawaM, ItoY, KumaS, TakamuraY, MiyaA, KobayashiK, MiyauchiA. 2010. Nodal metastasis in well-differentiated follicular carcinoma of the thyroid: its incidence and clinical significance. Oncol Lett, 1:873–876.
8.
LiVolsiVA, AsaSL. 1994. The demise of follicular carcinoma of the thyroid gland. Thyroid, 4:233–236.
9.
Aschebrook-KilfoyB, GroganRH, WardMH, KaplanE, DevesaSS. 2013. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid, 23:1015–1021.
10.
Feldt-RasmussenU. 2001. Iodine and cancer. Thyroid, 11:483–486.
11.
SantosJE. 2017. Thyroid cancer consequences of iodine deficiency — a persisting worldwide problem: characteristics in different populations, Portugal and South Africa. S Afr J Surg, 55:69.
12.
CibasES, AliSZ. 2017. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid, 27:1341–1346.
13.
ValderrabanoP, KhazaiL, ThompsonZJ, SharpeSC, TarasovaVD, OttoKJ, Hallanger-JohnsonJE, WadsworthJT, WenigBM, ChungCH, CentenoBA, McIverB. 2018. Cancer risk associated with nuclear atypia in cytologically indeterminate thyroid nodules: a systematic review and meta-analysis. Thyroid, 28:210–219.
14.
DanielsGH. 2011. What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract, 17:768–787.
15.
ConzoG, AveniaN, AnsaldoGL, CaloP, De PalmaM, DobrinjaC, DocimoG, GambardellaC, GrassoM, LombardiCP, PelizzoMR, PezzollaA, PezzulloL, PiccoliM, RosatoL, SicilianoG, SpieziaS, TartagliaE, TartagliaF, TestiniM, TronconeG, SignorielloG. 2017. Surgical treatment of thyroid follicular neoplasms: results of a retrospective analysis of a large clinical series. Endocrine, 55:530–538.
16.
TesslerFN, MiddletonWD, GrantEG, HoangJK, BerlandLL, TeefeySA, CronanJJ, BelandMD, DesserTS, FratesMC, HammersLW, HamperUM, LangerJE, ReadingCC, ScouttLM, StavrosAT. 2017. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White paper of the ACR TI-RADS Committee. J Am Coll Radiol, 14:587–595.
17.
HoangJK, LeeWK, LeeM, JohnsonD, FarrellS. 2007. US Features of thyroid malignancy: pearls and pitfalls. Radiographics, 27:847–860; discussion 861–845.
18.
JehSK, JungSL, KimBS, LeeYS. 2007. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. Korean J Radiol, 8:192–197.
KobayashiK, HirokawaM, YabutaT, MasuokaH, FukushimaM, KiharaM, HigashiyamaT, ItoY, MiyaA, AminoN, MiyauchiA. 2016. Tumor protrusion with intensive blood signals on ultrasonography is a strongly suggestive finding of follicular thyroid carcinoma. Med Ultrason, 18:25–29.
21.
AcquavivaG, VisaniM, RepaciA, RhodenKJ, de BiaseD, PessionA, GiovanniT. 2018. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology, 72:6–31.
ProiettiA, SartoriC, MacerolaE, BorrelliN, MaterazziG, VittiP, BasoloF. 2017. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms. Virchows Arch, 471:769–773.
28.
LiuD, YangC, BojdaniE, MuruganAK, XingM. 2013. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst, 105:1617–1627.
29.
PaesJE, RingelMD. 2008. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am, 37:375–387, viii-ix.
30.
NgeowJ, NiY, TohmeR, Song ChenF, BebekG, Eng C 2014 Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer. J Clin Endocrinol Metab, 99:E1316–1321.
31.
LloydRV, OsamuraRY, KlöppelG, RosaiJ (eds) 2017. WHO Classification of Tumours of Endocrine Organs, fourth edition). International Agency for Research on Cancer [IRAC], Lyon.
32.
PrescottJD, SadowPM, HodinRA, LeLP, GazRD, RandolphGW, StephenAE, ParangiS, DanielsGH, LubitzCC. 2012. BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery, 152:984–990.
33.
WreesmannVB, NixonIJ, RiveraM, KatabiN, PalmerF, GanlyI, ShahaAR, TuttleRM, ShahJP, PatelSG, GhosseinRA. 2015. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. Thyroid, 25:503–508.
34.
AhnHS, KimHJ, WelchHG. 2014. Korea's thyroid-cancer “epidemic”—-screening and overdiagnosis. N Engl J Med, 371:1765–1767.
35.
ThompsonLD, WienekeJA, PaalE, FrommeltRA, AdairCF, HeffessCS. 2001. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer, 91:505–524.
LangW, GeorgiiA, StauchG, KienzleE. 1980. The differentiation of atypical adenomas and encapsulated follicular carcinomas in the thyroid gland. Virchows Arch A Pathol Anat Histol, 385:125–141.
38.
LangBH, ShekTW, WuAL, WanKY. 2017. The total number of tissue blocks per centimetre of tumor significantly correlated with the risk of distant metastasis in patients with minimally invasive follicular thyroid carcinoma. Endocrine, 55:496–502.
39.
FrancB, de la SalmoniereP, LangeF, HoangC, LouvelA, de RoquancourtA, VildeF, HejblumG, ChevretS, ChastangC. 2003. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol, 34:1092–1100.
40.
HuangCC, HsuehC, LiuFH, ChaoTC, LinJD. 2011. Diagnostic and therapeutic strategies for minimally and widely invasive follicular thyroid carcinomas. Surg Oncol, 20:1–6.
41.
PaphavasitA, ThompsonGB, HayID, GrantCS, van HeerdenJA, IlstrupDM, SchleckC, GoellnerJR. 1997. Follicular and Hürthle cell thyroid neoplasms. Is frozen-section evaluation worthwhile?. Arch Surg, 132:674–678; discussion 678–680.
42.
CiprianiNA, AgarwalS, Dias-SantagataD, FaquinWC, SadowPM. 2017. Clear cell change in thyroid carcinoma: a clinicopathologic and molecular study with identification of variable genetic anomalies. Thyroid, 27:819–824.
43.
ItoY, HirokawaM, MasuokaH, YabutaT, FukushimaM, KiharaM, HigashiyamaT, TakamuraY, KobayashiK, MiyaA, MiyauchiA. 2013. Distant metastasis at diagnosis and large tumor size are significant prognostic factors of widely invasive follicular thyroid carcinoma. Endocr J, 60:829–833.
44.
KimHJ, SungJY, OhYL, KimJH, SonYI, MinYK, KimSW, ChungJH. 2014. Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck, 36:1695–1700.
45.
O'NeillCJ, VaughanL, LearoydDL, SidhuSB, DelbridgeLW, SywakMS. 2011. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol, 37:181–185.
46.
RobinsonA, SchneiderD, SippelR, ChenH. 2017. Minimally invasive follicular thyroid cancer: treat as a benign or malignant lesion?. J Surg Res 207:235–240.
47.
ZaydfudimV, FeurerID, GriffinMR, PhayJE. 2008. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery, 144:1070–1077; discussion 1077–1078.
48.
KuoEJ, RomanSA, SosaJA. 2013. Patients with follicular and Hürthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery, 154:1246–1253; discussion 1253–1244.
49.
GlomskiK, NoseV, FaquinWC, SadowPM. 2017. Metastatic follicular thyroid carcinoma and the primary thyroid gross examination: institutional review of cases from 1990 to 2015. Endocr Pathol, 28:177–185.
50.
LodewijkL, KluijfhoutWP, KistJW, StegemanI, PlukkerJT, Nieveen van DijkumEJ, BonjerHJ, BouvyND, SchepersA, de WiltJH, Netea-MaierRT, van der HageJA, BurgerJW, HoG, LeeWS, ShenWT, AronovaA, ZarnegarR, BenayC, MitmakerEJ, SywakMS, AnissAM, KruijffS, JamesB, GroganRH, BrunaudL, HochG, PandolfiC, RuanDT, JonesMD, GuerreroMA, ValkGD, Borel RinkesIH, VriensMR. 2016. Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm. Langenbecks Arch Surg, 401:365–373.
51.
Cameselle-TeijeiroJ, FachalC, Cabezas-AgricolaJM, Alfonsin-BarreiroN, AbdulkaderI, Vega-GliemmoA, HermoJA. 2015. Thyroid pathology findings in cowden syndrome: a clue for the diagnosis of the PTEN hamartoma tumor syndrome. Am J Clin Pathol, 144:322–328.
52.
NguyenXV, Roy ChoudhuryK, TesslerFN, HoangJK. 2018. Effect of tumor size on risk of metastatic disease and survival for thyroid cancer: implications for biopsy guidelines. Thyroid, 28:295–300.
53.
SongYS, LimJA, MinHS, KimMJ, ChoiHS, ChoSW, MoonJH, YiKH, ParkDJ, ChoBY, ParkYJ. 2017. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. Eur J Endocrinol, 177:465–473.
54.
MachensA, HolzhausenHJ, DralleH. 2005. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer, 103:2269–2273.
55.
PoddaM, SabaA, PorruF, RecciaI, PisanuA. 2015. Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors. World J Surg Oncol, 13:193.
56.
GoffredoP, CheungK, RomanSA, SosaJA. 2013. Can minimally invasive follicular thyroid cancer be approached as a benign lesion?: a population-level analysis of survival among 1,200 patients. Ann Surg Oncol, 20:767–772.
57.
GoffredoP, JillardC, ThomasS, ScheriRP, SosaJA, RomanS. 2016. Minimally invasive follicular carcinoma: predictors of vascular invasion and impact on patterns of care. Endocrine, 51:123–130.
58.
SopikV, Nofech-MozesS, SunP, NarodSA. 2016. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat, 155:175–185.
MazzaferriEL, KloosRT. 2001. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 86:1447–1463.
61.
GrantCS. 2015. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg, 4:52–62.
62.
KrajewskaJ, ChmielikE, JarzabB. 2017. Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?. Endocr Relat Cancer, 24:R387-R402.
63.
RobbinsRJ, WanQ, GrewalRK, ReibkeR, GonenM, StraussHW, TuttleRM, DruckerW, LarsonSM. 2006. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab, 91:498–505.
64.
XingM, AlzahraniAS, CarsonKA, ViolaD, EliseiR, BendlovaB, YipL, MianC, VianelloF, TuttleRM, RobenshtokE, FaginJA, PuxedduE, FugazzolaL, CzarnieckaA, JarzabB, O'NeillCJ, SywakMS, LamAK, Riesco-EizaguirreG, SantistebanP, NakayamaH, TufanoRP, PaiSI, ZeigerMA, WestraWH, ClarkDP, Clifton-BlighR, SidranskyD, LadensonPW, SykorovaV. 2013. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA, 309:1493–1501.
65.
MoonS, SongYS, KimYA, LimJA, ChoSW, MoonJH, HahnS, ParkDJ, ParkYJ. 2017. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid, 27:651–660.
SilverCE, OwenRP, RodrigoJP, RinaldoA, DevaneyKO, FerlitoA. 2011. Aggressive variants of papillary thyroid carcinoma. Head Neck, 33:1052–1059.
68.
VogrinA, BesicH, BesicN, MusicMM. 2016. Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms. Radiol Oncol, 50:269–273.
69.
SabraMM, DominguezJM, GrewalRK, LarsonSM, GhosseinRA, TuttleRM, FaginJA. 2013. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab, 98:E829–836.
70.
SabraMM, GhosseinR, TuttleRM. 2016. Time course and predictors of structural disease progression in pulmonary metastases arising from follicular cell-derived thyroid cancer. Thyroid, 26:518–524.
71.
SciutoR, RomanoL, ReaS, MarandinoF, SperdutiI, MainiCL. 2009. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol, 20:1728–1735.
72.
SuginoK, ItoK, NagahamaM, KitagawaW, ShibuyaH, OhkuwaK, YanoY, UrunoT, AkaishiJ, KameyamaK, ItoK. 2011. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid, 21:751–757.
73.
YuXF, WangWB, TengXD, WangHY, ChenX, WangHH, MaZM, FaheyTJ3rd, TengLS. 2014. Clinicopathological and prognostic analysis of follicular thyroid carcinoma in a single institute over a 15-year period. Eur J Surg Oncol, 40:869–874.
74.
van HeerdenJA, HayID, GoellnerJR, SalomaoD, EbersoldJR, BergstralhEJ, GrantCS. 1992. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery, 112:1130–1136; discussion 1136–1138.
XuB, TuttleRM, SabraMM, GanlyI, GhosseinR. 2017. Primary thyroid carcinoma with low-risk histology and distant metastases: clinicopathologic and molecular characteristics. Thyroid, 27:632–640.
77.
FukahoriM, YoshidaA, HayashiH, YoshiharaM, MatsukumaS, SakumaY, KoizumeS, OkamotoN, KondoT, MasudaM, MiyagiY. 2012. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid, 22:683–689.
78.
MeloM, Gaspar da RochaA, BatistaR, VinagreJ, MartinsMJ, CostaG, RibeiroC, CarrilhoF, LeiteV, LoboC, Cameselle-TeijeiroJM, CavadasB, PereiraL, Sobrinho-SimoesM, SoaresP. 2017. TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease. J Clin Endocrinol Metab, 102:1898–1907.
79.
JungSH, KimMS, JungCK, ParkHC, KimSY, LiuJ, BaeJS, LeeSH, KimTM, LeeSH, ChungYJ. 2016. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. Oncotarget, 7:69638–69648.
80.
Van WyngaardenK, McDougallIR. 1997. Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue?. Thyroid, 7:343–346.
81.
BarbesinoG, GoldfarbM, ParangiS, YangJ, RossDS, DanielsGH. 2012. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up. Thyroid, 22:369–376.
82.
BaekHJ, KimDW, LeeS, RyooI, LeeCY, ChoiYJ, SungJY. 2017. Postoperative ultrasonography surveillance in patients with follicular thyroid carcinoma: a multicenter study. Radiol Med, 122:530–537.
83.
TuttleRM, HaugenB, PerrierND. 2017. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?. Thyroid, 27:751–756.
84.
LangBH, LoCY, ChanWF, LamKY, WanKY. 2007. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer, 14:29–42.
85.
McLeodDS, JonklaasJ, BrierleyJD, AinKB, CooperDS, FeinHG, HaugenBR, LadensonPW, MagnerJ, RossDS, SkarulisMC, StewardDL, XingM, LitofskyDR, MaxonHR, ShermanSI. 2015. Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis. Thyroid, 25:1097–1105.
86.
NiepomniszczeH, SuarezH, PitoiaF, PignattaA, DanilowiczK, ManavelaM, ElsnerB, BrunoOD. 2006. Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid, 16:497–503.
87.
SpambalgD, SharifiN, EliseiR, GrossJL, Medeiros-NetoG, FaginJA. 1996. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab, 81:3898–3901.
88.
IshiharaT, IkekuboK, ShimodahiraM, IwakuraT, KobayashiM, HinoM, OobayashiM, KohnoK, KimuraK, KawamuraS, KurahachiH. 2002. A case of TSH receptor antibody-positive hyperthyroidism with functioning metastases of thyroid carcinoma. Endocr J, 49:241–245.
89.
StathatosN, GazR, RossDS, DanielsGH. 2011. High radioactive iodine uptake despite a fully suppressed TSH in a patient with thyroid cancer. J Clin Endocrinol Metab, 96:589.
90.
KimBW, DanielsGH, HarrisonBJ, PriceA, HarneyJW, LarsenPR, WeetmanAP. 2003. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab, 88:594–598.
91.
MiyauchiA, TakamuraY, ItoY, MiyaA, KobayashiK, MatsuzukaF, AminoN, ToyodaN, NomuraE, NishikawaM. 2008. 3,5,3′-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab, 93:2239–2242.
92.
DanilovicDL, de CamargoRY, CastroGJr., PapadiaC, MaruiS, HoffAO. 2015. Rapid control of T3 thyrotoxicosis in patients with metastatic follicular thyroid cancer treated with lenvatinib. Thyroid, 25:1262–1264.
93.
CeliFS, ZemskovaM, LindermanJD, BabarNI, SkarulisMC, CsakoG, WesleyR, CostelloR, PenzakSR, PucinoF. 2010. The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. Clin Endocrinol (Oxf), 72:709–715.
94.
BushbyKM, ColeT, MatthewsJN, GoodshipJA. 1992. Centiles for adult head circumference. Arch Dis Child, 67:1286–1287.
McFaddenDG, Dias-SantagataD, SadowPM, LynchKD, LubitzC, DonovanSE, ZhengZ, LeL, IafrateAJ, Daniels GH 2014 Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab, 99:E2457–2462.
97.
AsaSL, GiordanoTJ, LiVolsiVA. 2015. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist?. Thyroid, 25:1–2.
98.
DanielsGH. 2016. Follicular variant of papillary thyroid carcinoma: hybrid or mixture?. Thyroid, 26:872–874.
99.
NikiforovYE, SeethalaRR, TalliniG, BalochZW, BasoloF, ThompsonLD, BarlettaJA, WenigBM, Al GhuzlanA, KakudoK, GiordanoTJ, AlvesVA, KhanafsharE, AsaSL, El-NaggarAK, GoodingWE, HodakSP, LloydRV, MaytalG, MeteO, NikiforovaMN, NoseV, PapottiM, PollerDN, SadowPM, TischlerAS, TuttleRM, WallKB, LiVolsiVA, RandolphGW, GhosseinRA. 2016. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol, 2:1023–1029.
100.
Albores-SaavedraJ, HensonDE, GlazerE, SchwartzAM. 2007. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype–papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol, 18:1–7.
101.
KimMJ, WonJK, JungKC, KimJH, ChoSW, ParkDJ, ParkYJ. 2018. Clinical characteristics of subtypes of follicular variant papillary thyroid carcinoma. Thyroid, 28:311–318.
102.
LiuJ, SinghB, TalliniG, CarlsonDL, KatabiN, ShahaA, TuttleRM, GhosseinRA. 2006. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer, 107:1255–1264.
103.
BalochZW, LiVolsiVA. 2000. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol, 13:861–865.
104.
GasparreG, PorcelliAM, BonoraE, PennisiLF, TollerM, IommariniL, GhelliA, MorettiM, BettsCM, MartinelliGN, CeroniAR, CurcioF, CarelliV, RugoloM, TalliniG, RomeoG. 2007. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA, 104:9001–9006.
105.
CorverWE, RuanoD, WeijersK, den HartogWC, van NieuwenhuizenMP, de MirandaN, van EijkR, MiddeldorpA, JordanovaES, OostingJ, KapiteijnE, HovensG, SmitJ, van WezelT, MorreauH. 2012. Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PLoS One, 7:e38287.
106.
GanlyI, Ricarte FilhoJ, EngS, GhosseinR, MorrisLG, LiangY, SocciN, KannanK, MoQ, FaginJA, ChanTA. 2013. Genomic dissection of Hürthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab, 98:E962–972.
107.
ChindrisAM, CaslerJD, BernetVJ, RiveraM, ThomasC, KachergusJM, NecelaBM, HayID, WestphalSA, GrantCS, ThompsonGB, SchlinkertRT, ThompsonEA, SmallridgeRC. 2015. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. J Clin Endocrinol Metab, 100:55–62.
108.
Ernaga LoreaA, Migueliz BermejoI, Anda ApinanizE, Pineda ArribasJ, Toni GarciaM, Martinez de EstebanJP, Insausti SerranoAM. 2018. Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma. Endocrinol Diabetes Nutr, 65:136–142.
109.
NagarS, Aschebrook-KilfoyB, KaplanEL, AngelosP, GroganRH. 2013. Hürthle cell carcinoma: an update on survival over the last 35 years. Surgery, 154:1263–1271; discussion 1271.
110.
VolanteM, BussolatiG, PapottiM. 2016. The story of poorly differentiated thyroid carcinoma: From Langhans' description to the Turin proposal via Juan Rosai. Semin Diagn Pathol, 33:277–283.
111.
CampbellWJ. 2006. The Year That Defined American Journalism 1897 and the Clash of Paradigms. Taylor & Francis Group, New York.
